INTRODUCTION
The WHO estimates over 650 million people globally and more than 29 million Europeans have chronic liver disease [1] . Alarming increases in obesity rates and in tandem, increases in rates of non-alcoholic fatty liver disease (NAFLD), plus an ageing population mean that liver disease will become an even greater health concern over the next decade [2] . NAFLD is a spectrum of liver disease ranging from steatosis, through non-alcoholic steatohepatitis (NASH) to cirrhosis, and possible hepatocellular carcinoma. The prognosis of patients with simple steatosis appears good whereas NASH often has a progressive course with increased liver-related morbidity and mortality [3] [4] [5] . Given the increasing population prevalence of NAFLD and NASH, the ability to treat NASH would be a significant clinical breakthrough. Treatment options for NASH are limited to life-style modifications with no approved targeted drug therapy available. This article focuses on recent studies that provide the basis for proposing targeting of ammonia as a new therapeutic approach for NASH.
BACKGROUND
NAFLD is a condition characterized by fatty acid uptake, de novo fatty acid synthesis and reduced beta-oxidation leading to increased liver fat in patients that are not consuming excessive alcohol. The pathophysiological diagnosis of NASH refers to the presence of histological inflammation, pericellular fibrosis and liver injury super imposed on vesicular fat laden hepatocytes characteristic of NAFLD [6] . Recently, NASH has been defined as a "multiple parallel hits" disease that can progress to liver fibrosis, which develops primarily in the pericentral areas, surrounding groups of hepatocytes and thickening of the space of Disse with eventual nodule formation [7] . The development of advanced fibrosis is the most important factor contributing to NASH-associated morbidity and mortality [8] . The main cell type responsible for extracellular matrix deposition are hepatic stellate cells (HSC) , that undergo activation in conditions of frank hepatocellular injury, enabling them to participate in the wound healing process [9] . HSCs are key in maintaining architectural integrity and in the development of fibrosis, portal hypertension and liver cancer [10] [11] [12] and reduction in their activation is a target for therapy.
The Urea cycle, as a complete process running exclusively in the liver, has evolved in mammals to ultimately remove ammonia through conversion of excess amino-nitrogen to urea. The cycle comprises 5 enzymes, the first and the last of which reside in the mitochondria -cabamoylphosphate synthetase (CPS) and ornithine transcarbamoylase (OTC) [13] . In liver failure patients, ammonia accumulates through reduction in the function of the urea cycle due to a reduction in liver cell mass, producing numerous deleterious effects ranging from hepatic encephalopathy to neutrophil dysfunction and loss of muscle mass [14] [15] [16] [17] . Genetic OTC deficiency is the most common type of inherited urea cycle enzyme deficiency disease and is manifest by catastrophic hyperammonemia and hepatic encephalopathy. In the adult form of OTC deficiency, milder degrees of hyperammonemia are manifest [18] .
In NASH, many lines of investigation indicate that mitochondria are dysfunctional [19] and it is, therefore, possible that the resultant mitochondrial injury may affect CPS and OTC function, and in turn, result in compromised urea synthesis capacity and ultimately hyperammonemia. As mitochondria are mandatory for the production of cellular energy through β-oxidation of fatty acids, disruption in their function is often accompanied by an enhanced production of reactive oxygen species (ROS), which mediates a proinflammatory microenvironment, promoting further liver injury.
Emerging data suggests a link between NASH, reduction in gene expression and function of urea cycle enzymes, resulting in hyperammonemia and progression of liver injury and fibrosis. This supports a rationale for targeting ammonia as a potential treatment for NASH. The mechanism is likely to be specific for liver disease in which triglycerides accumulate in hepatocytes and the liver becomes steatotic thereby reducing the function of urea synthesis leading to hyperammonemia at a pre-cirrhotic stage. Long-chain fatty acids promote perturbations in urea cycle enzyme gene expression resulting in hyperammonemia [20] , whereas hepatic triglyceride accumulation (as is the case in NASH) is known to inhibit ureagenesis and increase ammonia concentrations around perivenous hepatocytes [21] . Hyperammonemia is associated with alteration of several genes including the Toll-like receptor pathway and increased hepatocyte apoptosis [22] . In urea cycle enzyme knock out mice, induction of chronic liver injury leads to increased oxidative stress, impaired fatty acid β-oxidation and enhanced liver injury compared to wild type mice [23] and likewise, livers from patients with urea cycle disorders, including OTC deficiency, demonstrate extensive hepatic fibrosis and cirrhosis [24] .
OBSERVATIONS LEADING UP TO THE HYPOTHESES
Evidence that NASH results in hyperammonemia and a reversible reduction in activity and function of urea cycle enzymes 1. We have previously shown experimentally that diet-induced NASH in rats reduces CPS and particularly OTC gene and protein expression resulting in functional reduction in the in vivo capacity for ureagenesis [25] . This impairs nitrogen homeostasis and results in hyperammonemia at a non-cirrhotic stage, Figure 1A and B. A follow-on study demonstrated that these changes were reversible upon recovery from NASH, and that reversal of NASH by reversion of the fat diet to normal chow, restored CPS and OTC gene and protein expression [26] . 4. The reduced urea cycle enzyme expression in patients with NASH gives rise to a reduced ammonia clearance. In patients with biopsy-proven, non-cirrhotic NASH. Felipo et al. found higher plasma ammonia levels compared to patients with simple steatosis and age-matched controls [28] . Additionally, these non-cirrhotic NASH patients showed evidence of neuropsychiatric disturbances that are commonly associated with hyperammonemia in the context of cirrhosis.
Evidence that ammonia produces functional and morphological changes in human HSCs
Pathological levels of ammonia are known to induce metabolic effects and cell swelling in astrocytes in the brain, which is central in the pathogenesis of hepatic encephalopathy [29] . Several studies have indicated that astrocytes and HSCs share a similar mesodermal origin and express similar cell markers of activation [30, 31] . We have recently 
Evidence that reduction of ammonia concentration in vivo reduces stellate cell activation and reduces portal hypertension
We undertook an in vivo study to establish if the ammonia scavenging drug ornithine phenylacetate (OP) was able to prevent the activation of HSC. Four-week bile duct ligated rats with advanced fibrosis and hyperammonemia were treated with OP and we observed reduced plasma ammonia, abrogated tissue markers of HSC activation and significantly reduced portal pressure indicating that targeting ammonia in vivo reduces HSC activation and may also be beneficial for treatment of portal hypertension [32] , Figure 5 .
THE HYPOTHESIS
The data presented above shows that NASH produces a reversible reduction in the expression and function of urea cycle enzymes resulting in decreased ammonia elimination and ultimately hyperammonemia at a non-cirrhotic stage. Ammonia produces morphological changes and further activation of HSCs, which, in the context of NASH, by means of their pro-fibrotic and pro-inflammatory potential, may favour the progression of NASH. It follows that ammonia scavenging may represent a therapeutic target in NASH, Figure 6 .
Hypothesis:
1. Administration of an ammonia-lowering drug in NASH reduces disease progression through non-urea ammonia scavenging and thereby reduction in activation of HSCs.
DISCUSSION
Our hypothesis provides the rationale for targeting ammonia as a potential treatment for NASH. We suggest that hyperammonemia is present in NASH at the non-cirrhotic stage and that ammonia is an important molecule involved in the progression towards development of fibrosis. We believe this mechanism is specific for steatotic liver diseases and ammonia scavenging could therefore also be an anti-fibrotic therapy in e.g. alcoholic steatohepatitis. In contrast, in patients with decompensated cirrhosis ammonia lowering is a strategy for the treatment of hepatic encephalopathy. Extra cerebral effects of ammonia have not been fully appreciated [14, 33] . More recently, pathophysiological concentrations of ammonia were shown to result in neutrophil dysfunction both in vivo and in vitro [16] .
Also, Dasarathy et al. have shown that ammonia is important in the muscle metabolism and may be a target to treat sarcopenia [34] . OP has been proven to reduce ammonia levels in animals with acute-on-chronic and acute liver failure [35, 36] , and our findings indicate that this may also reduce activation of HSCs [32] . Preliminary data from our own laboratories have shown similar results in a NASH animal model [37] . Also in humans, OP is considered safe and beneficial as an ammonia scavenger to treat hyperammonemia in healthy subjects and patients with cirrhosis [38] . Therefore, the potential for early translation to test our hypothesis in NASH patients is not far away, especially as other ammonia lowering agents e.g. lactulose are already used as standard-of-care in the prevention and treatment of hyperammonemia and hepatic encephalopathy in cirrhotic patients. (controls) or a HFC diet for 16 weeks assessed using Nessler's reagent [39] . In controls, ammonia is present in red blood cells only (pale-yellow, black arrows). In HFC-fed animals, ammonia is diffusively scattered in the hepatic parenchyma and tends to accumulate in the walls of vessels (black arrows) (B). 
